Jacques is the President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (Akari), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene systems (LBT4) are implicated, and also serves on their Board of Directors
Originally developed in the 1980s as part of a search for GH-releasing drugs, GHRP-6 acts by binding to the GHS-R1a receptor (growth hormone secretagogue receptor), which triggers pulsatile GH release in a pattern similar to how your body naturally releases it during sleep or fasting
Phase II Conjugation Enzymes8 Methyltransferase Detoxification Enzymes and Methylation Capacity A cells methylation capacity is defined as the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH)
Professional handling and packaging practices designed to help maintain peptide stability and integrity during storage and transit
Therapeutic targets of human AKI: harmonizing human and animal AKI
Brain connectivity changes to fast versus slow dopamine increases